Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.CTQLEHs_.js ...

On Vertex's Q4 earnings call, investors will focus on management's comments about launch preparation for Alyftrek (vanza ...

The upcoming report from Vertex Pharmaceuticals (VRTX) is expected to reveal quarterly earnings of $3.99 per share, indicating a decline of 5% compared to the year-ago period. Analysts forecast ...

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

The S&P 500 index trades at a forward price/earnings ratio of 21.9. The U.S. large-cap benchmark stock index is weighted by market capitalization. The index's current forward P/E valuation is 18% ...

AbbVie, Vertex Pharmaceuticals, and Thermo Fisher Scientific are the three Biotech stocks to watch today, according to ...

Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 20 years ago, it would be worth $4,232.95 today based on a ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...